[{"indications": "Indications\u00a0prophylaxis of acute renal, cardiac, or hepatic\r\ntransplant rejection (in combination with ciclosporin and corticosteroids) under specialist supervision", "name": "MYCOPHENOLATE MOFETIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.1 Antiproliferative immunosuppressants", "MYCOPHENOLATE MOFETIL"], "cautions": "Cautions\u00a0see Bioavailability; full blood counts every week for 4 weeks then twice a month for 2\r\nmonths then every month in the first year (consider interrupting treatment if neutropenia develops); exclude pregnancy before starting treatment; elderly (increased risk of infection,\r\ngastro-intestinal haemorrhage and pulmonary oedema); children (higher incidence of side-effects may call\r\nfor temporary reduction of dose or interruption); active\r\nserious gastro-intestinal disease (risk of haemorrhage,\r\nulceration and perforation); delayed graft function; increased susceptibility to skin cancer (avoid exposure to strong sunlight); interactions: Appendix 1 (mycophenolate)Bone marrow suppression\u00a0Patients\r\nshould be warned to report immediately any signs or symptoms of bone\r\nmarrow suppression e.g. infection or inexplicable bruising or bleeding", "side-effects": "Side-effects\u00a0taste disturbance, gingival hyperplasia, nausea,\r\nconstipation, flatulence, anorexia, weight loss, vomiting, abdominal\r\npain, gastro-intestinal inflammation, ulceration, and bleeding, hepatitis,\r\njaundice, pancreatitis, stomatitis, oedema, tachycardia, hypertension,\r\nhypotension, vasodilatation, cough, dyspnoea, insomnia, agitation,\r\nconfusion, depression, anxiety, convulsions, paraesthesia, myasthenic\r\nsyndrome, tremor, dizziness, headache, influenza-like syndrome, infections,\r\nhyperglycaemia, renal impairment, malignancy (particularly of the\r\nskin), blood disorders (including leucopenia, anaemia, thrombocytopenia,\r\npancytopenia, and red cell aplasia\u2014\n(From 8.2.1 Antiproliferative immunosuppressants: British National Formulary)\nMycophenolate mofetil  is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine. It is licensed for the prophylaxis of acute rejection in renal, hepatic or cardiac transplantation when used in combination with ciclosporin and corticosteroids. There is evidence that compared with similar regimens incorporating azathioprine, mycophenolate mofetil reduces the risk of acute rejection episodes; the risk of opportunistic infections (particularly due to tissue-invasive cytomegalovirus) and the occurrence of blood disorders such as leucopenia may be higher.Cases of pure red cell aplasia have been reported with azathioprine and with mycophenolate mofetil; dose reduction or discontinuation should be considered under specialist supervision.), disturbances of electrolytes\r\nand blood lipids, arthralgia, alopecia, acne, skin hypertrophy, and\r\nrash; also reported intestinal villous atrophy, progressive\r\nmultifocal leucoencephalopathy, interstitial lung disease, pulmonary\r\nfibrosis ", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/38697.htm", "doses": ["Renal transplantation, by mouth, 1\u00a0g twice\r\ndaily starting within 72 hours of transplantation or by intravenous infusion, 1\u00a0g twice daily starting\r\nwithin 24 hours of transplantation for max. 14 days (then transfer\r\nto oral therapy); child and adolescent 2\u201318 years, by mouth 600\u00a0mg/m2 twice daily (max. 2\u00a0g daily)", "Tablets and capsules not appropriate for\r\ndose titration in children with body surface area less than 1.25\u00a0m2", "Cardiac transplantation, by mouth, adult over 18 years, 1.5\u00a0g twice daily starting within\r\n5 days of transplantation", "Hepatic transplantation, by intravenous infusion, adult over 18 years, 1\u00a0g twice daily\r\nstarting within 24 hours of transplantation for 4 days (up to max.\r\n14 days), then by mouth, 1.5\u00a0g twice daily as soon\r\nas is tolerated"], "pregnancy": "Pregnancy\u00a0avoid\u2014congenital malformations reported; effective\r\ncontraception required before treatment, during treatment, and for\r\n6 weeks after discontinuation of treatment"}, {"indications": "Indications\u00a0prophylaxis of acute renal, cardiac, or hepatic\r\ntransplant rejection (in combination with ciclosporin and corticosteroids) under specialist supervision", "name": "MYCOPHENOLATE MOFETIL Mycophenolic acid", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.1 Antiproliferative immunosuppressants", "MYCOPHENOLATE MOFETIL", "Mycophenolic acid"], "cautions": "Cautions\u00a0see Bioavailability; full blood counts every week for 4 weeks then twice a month for 2\r\nmonths then every month in the first year (consider interrupting treatment if neutropenia develops); exclude pregnancy before starting treatment; elderly (increased risk of infection,\r\ngastro-intestinal haemorrhage and pulmonary oedema); children (higher incidence of side-effects may call\r\nfor temporary reduction of dose or interruption); active\r\nserious gastro-intestinal disease (risk of haemorrhage,\r\nulceration and perforation); delayed graft function; increased susceptibility to skin cancer (avoid exposure to strong sunlight); interactions: Appendix 1 (mycophenolate)Bone marrow suppression\u00a0Patients\r\nshould be warned to report immediately any signs or symptoms of bone\r\nmarrow suppression e.g. infection or inexplicable bruising or bleeding", "side-effects": "Side-effects\u00a0taste disturbance, gingival hyperplasia, nausea,\r\nconstipation, flatulence, anorexia, weight loss, vomiting, abdominal\r\npain, gastro-intestinal inflammation, ulceration, and bleeding, hepatitis,\r\njaundice, pancreatitis, stomatitis, oedema, tachycardia, hypertension,\r\nhypotension, vasodilatation, cough, dyspnoea, insomnia, agitation,\r\nconfusion, depression, anxiety, convulsions, paraesthesia, myasthenic\r\nsyndrome, tremor, dizziness, headache, influenza-like syndrome, infections,\r\nhyperglycaemia, renal impairment, malignancy (particularly of the\r\nskin), blood disorders (including leucopenia, anaemia, thrombocytopenia,\r\npancytopenia, and red cell aplasia\u2014\n(From 8.2.1 Antiproliferative immunosuppressants: British National Formulary)\nMycophenolate mofetil  is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine. It is licensed for the prophylaxis of acute rejection in renal, hepatic or cardiac transplantation when used in combination with ciclosporin and corticosteroids. There is evidence that compared with similar regimens incorporating azathioprine, mycophenolate mofetil reduces the risk of acute rejection episodes; the risk of opportunistic infections (particularly due to tissue-invasive cytomegalovirus) and the occurrence of blood disorders such as leucopenia may be higher.Cases of pure red cell aplasia have been reported with azathioprine and with mycophenolate mofetil; dose reduction or discontinuation should be considered under specialist supervision.), disturbances of electrolytes\r\nand blood lipids, arthralgia, alopecia, acne, skin hypertrophy, and\r\nrash; also reported intestinal villous atrophy, progressive\r\nmultifocal leucoencephalopathy, interstitial lung disease, pulmonary\r\nfibrosis ", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129180.htm", "doses": ["Renal transplantation, by mouth, 1\u00a0g twice\r\ndaily starting within 72 hours of transplantation or by intravenous infusion, 1\u00a0g twice daily starting\r\nwithin 24 hours of transplantation for max. 14 days (then transfer\r\nto oral therapy); child and adolescent 2\u201318 years, by mouth 600\u00a0mg/m2 twice daily (max. 2\u00a0g daily)", "Tablets and capsules not appropriate for\r\ndose titration in children with body surface area less than 1.25\u00a0m2", "Cardiac transplantation, by mouth, adult over 18 years, 1.5\u00a0g twice daily starting within\r\n5 days of transplantation", "Hepatic transplantation, by intravenous infusion, adult over 18 years, 1\u00a0g twice daily\r\nstarting within 24 hours of transplantation for 4 days (up to max.\r\n14 days), then by mouth, 1.5\u00a0g twice daily as soon\r\nas is tolerated", "Mycophenolic\r\nacid 720\u00a0mg is approximately equivalent to mycophenolate mofetil 1\u00a0g\r\nbut avoid unnecessary switching because of pharmacokinetic differences", "Name[Myfortic\u00ae (Novartis) ] Tablets, e/c, mycophenolic acid\r\n(as mycophenolate sodium) 180\u00a0mg (green), net price 120-tab pack =\r\n\u00a396.72; 360\u00a0mg (orange), 120-tab pack = \u00a3193.43. \r\n    Label:\r\n    25Dose\u00a0renal transplantation, 720\u00a0mg twice daily starting within\r\n72 hours of transplantationEquivalence to mycophenolate mofetil\u00a0Mycophenolic\r\nacid 720\u00a0mg is approximately equivalent to mycophenolate mofetil 1\u00a0g\r\nbut avoid unnecessary switching because of pharmacokinetic differences"], "pregnancy": "Pregnancy\u00a0avoid\u2014congenital malformations reported; effective\r\ncontraception required before treatment, during treatment, and for\r\n6 weeks after discontinuation of treatment"}]